Seres Therapeutics (MCRB) Research & Development (2014 - 2026)

Seres Therapeutics has reported Research & Development for 13 years, with the latest figure at $13.2 million in Q1 2026.

• Quarterly Research & Development rose 11.62% year-over-year to $13.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50.4 million (down 11.41% YoY) and the FY2025 annual result came in at $49.1 million, down 24.06% from the prior year.
• Research & Development advanced to $13.2 million in Q1 2026 per MCRB's latest filing, from $11.7 million in the prior quarter.
• Over five years, Research & Development peaked at $46.8 million in Q2 2023 and troughed at -$17.0 million in Q4 2022.
• A 5-year average of $20.4 million and a median of $15.8 million in 2024 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2023: Research & Development tumbled 146.39% in 2022, then jumped 235.16% in 2023.
• Over 5 years, Research & Development stood at -$17.0 million in 2022, then surged by 235.16% to $23.0 million in 2023, then tumbled by 44.27% to $12.8 million in 2024, then dropped by 9.01% to $11.7 million in 2025, then rose by 12.93% to $13.2 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $13.2 million, $11.7 million, and $12.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.